| Document |
Document Title |
|
WO/1999/020270A1 |
The present invention relates to tricyclic carbapenem antibacterial agents in which the carbapenem nucleus is fused to a 6 membered carbocyclic ring. The compound is further substituted with various substituent groups including at least ...
|
|
WO/1999/020612A1 |
The present invention relates to a compound of Formula (1) wherein Ar?1¿ represents: (A) or (B) or (C); R?1¿ is hydrogen, C¿1-4?alkyl or C¿1-4?alkanoyl; R?12¿ and R?13¿ are independently hydrogen or C¿1-4?alkyl; Ar?2¿ is phenyl o...
|
|
WO/1999/019296A1 |
Aminobutanoic acid derivatives represented by general formula (I) and salts thereof (wherein each symbol is as defined in the description). The derivatives inhibit matrix metalloproteinases and are therefore useful for the prevention and...
|
|
WO/1999/019303A1 |
Drugs, in particular, pyrazole derivatives represented by general formula (I) which have a calcium release-dependent calcium channel inhibitory effect and medicinal compositions, in particular, calcium release-dependent calcium channel i...
|
|
WO/1999/017777A1 |
The present invention is directed to compounds which inhibit a prenyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compou...
|
|
WO/1999/018081A1 |
Substituted fused heterocyclic compounds represented by general formula (I) or pharmacologically acceptable salts thereof, excellent in the effects of ameliorating insulin resistance, inhibiting 5-lipoxygenase, and suppressing lipid pero...
|
|
WO/1999/018111A1 |
The crystalline polymorph of (-)-2S-[4-[4- [4-[4-[ [(R-CIS)-5-(2, 4-difluorophenyl) tetrahydro-5-(1H-1, 2,4-triazol-1- ylmethyl)-3-furanyl] methoxy]phenyl] -1-piperazinyl] phenyl-4,5-dihydro-5- oxo-1H-1, 2,4-triazol-l-yl] -1(S)-methylbut...
|
|
WO/1999/018091A1 |
This invention relates to novel phenyl oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuro-protective agents.
|
|
WO1998054161A9 |
The present invention provides compounds of Formula (I) or pharmaceutical acceptable salts thereof wherein A, G and R1 are as defined in the claims which are antibacterial agents.
|
|
WO/1999/015500A1 |
Compounds of formula (I): wherein X is N, CH, CCF¿3?, or C(C¿1-12? aliphatic); R?4¿ is sulfonic acid, C¿1-12? aliphatic-sulfonyl, sulfonyl-C¿1-12? aliphatic, C¿1-12? aliphatic-sulfonyl-C¿1-6? aliphatic, C¿1-6? aliphatic-amino, R?...
|
|
WO/1999/014217A1 |
The present invention relates to carbapenem antibacterial agents of formula (I), as well as salts and hydrates thereof. Pharmaceutical compositions and methods of treatment are also included.
|
|
WO/1999/012915A1 |
The invention relates to compounds of the formula formula (I) and to their production and their use in pharmaceuticals.
|
|
WO/1999/011632A1 |
Excitatory amino acid receptors comprising as the active ingredient 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives or addition salts thereof, particularly compounds exhibiting antagonism against AMPA receptors; a...
|
|
WO/1999/011645A1 |
This invention relates to compounds, pharmaceutical compositions, and methods of using compounds of formula (I), or a pharmaceutically acceptable salt, hydrate, prodrug, or mixtures thereof, wherein: Y is alkylhalo, alkyl-CO-G, COG, a di...
|
|
WO/1999/011606A2 |
The present invention comprises small molecular weight, non-peptidic inhibitors of formula (I) and (II) of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Melli...
|
|
WO/1999/010327A1 |
The invention relates to substituted 2-benzoyl-cyclohexane-1,3-dione of formula (I), in which the substituents have the meaning indicated in the description, the agriculturally usable salts thereof, the production and the intermediary pr...
|
|
WO/1999/010325A1 |
Compounds of general formula (I) wherein: R?1¿ is H or optionally joined with R?2¿ to form a fused ring selected from the group consisting of five to ten membered aryl, heteroaryl or heterocyclyl rings, R?2¿ and R?3¿ are independentl...
|
|
WO/1999/010328A1 |
The invention relates to substituted 4-benzoyl-pyrazole of formula (I), in which the substituents have the meaning indicated in the description, the agriculturally usable salts thereof, the production and the intermediary products used f...
|
|
WO/1999/008678A1 |
The invention is concerned with the use of compounds of general formula (I), wherein R signifies halogen or lower alkyl; n signifies 0-3; R?1¿ signifies lower alkyl; cycloalkyl; benzyl optionally substituted by hydroxy, halogen, lower a...
|
|
WO/1999/007677A1 |
Disclosed are non-peptidyl 2-acylaminopropanamine tachykinin receptor antagonists which are useful in the treatment of various conditions including Alzheimer's disease, and pharmaceutical compositions containing such compounds.
|
|
WO/1999/007672A1 |
Substituted anilines of general formula (I) wherein R?1¿, R?2¿, R?3¿, R?4¿ and X are defined in the description, compositions thereof and methods for preparing the compounds are described. The compounds are useful for the treatment o...
|
|
WO/1999/005096A2 |
Compounds having formula (I) are inhibitors of urokinase and are useful in the treatment of diseases in which urokinase plays a role. Also disclosed are urokinase-inhibiting compositions and a method of inhibiting urokinase in a mammal.
|
|
WO/1999/003835A1 |
Novel uses of aromatic ketone derivatives, especially as a remedy for frequent urination or urinary incontinence or as a calcium antagonist; and novel aromatic ketone derivatives suitable for these uses. Typically aromatic ketone derivat...
|
|
WO/1999/003836A1 |
The invention concerns novel monobenzene oxidation bases comprising at least a cationic group Z, Z being selected among the aliphatic chains containing at least a quaternized unsaturated cycle, their use for oxidation dyeing of keratin f...
|
|
WO/1999/003845A1 |
Compounds of formula (I) wherein: R?1¿ represents a group of formula (II), (III), (IV) or (V) or a corresponding formula (IVa) or (Va) in which the position of the carbonyl group and the group Q are reversed and the double bond in the r...
|
|
WO/1999/003834A2 |
The invention concerns novel di-benzene oxidation bases comprising at least a cationic group Z, Z being selected among quaternized aliphatic chains, aliphatic chains containing at least one quaternized saturated cycle, and aliphatic chai...
|
|
WO/1999/003856A1 |
Compounds of formula (I) wherein A represents a group (A-1), (A-2), (A-3) or (A-4); z represents one or two; when z represents two the XR?3¿ groups may be the same or different; R?3¿ represents a 5-membered heteroaromatic ring of formu...
|
|
WO/1999/002155A1 |
The present invention relates to imidazole derivatives having formula (1) or its pharmaceutically acceptable salts. These compounds are useful for restoring the sensitivity of multidrug resistant cells to cancer chemotherapeutic agents.
|
|
WO/1999/002524A1 |
Triazole compounds with excellent antifungal activities represented by general formula (I) or pharmacologically acceptable salts thereof; compositions for preventing or treating fungal infection which contain the above compounds as the a...
|
|
WO/1999/002528A1 |
The invention relates to novel triazole derivatives of formula (I), their use as medicaments, pharmaceutical compositions containing them and methods for their preparation.
|
|
WO/1999/002496A1 |
The present invention concerns (+)-norcisapride of formula (I) and compounds (V), and its pharmaceutically acceptable acid additions salts, a process for preparing said compound, and its use for the manufacture of a medicament for treati...
|
|
WO/1999/002523A1 |
The present invention concerns novel compounds of formula (I), a $i(N)-oxide form, a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof, wherein n is zero, 1, 2 or 3; X is N or CH; each R?1¿ indep...
|
|
WO/1999/001103A2 |
The present invention relates to peptide derivatives of general formula (I) as well as to pharmaceutically acceptable salts thereof. This invention also relates to the use of said derivatives as agents which have an anti-oxidising, anti-...
|
|
WO/1999/001428A1 |
Hydrazine derivatives of formula (I) wherein Y signifies CO or SO¿2?; R?1¿ signifies lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R?2¿ signifies lower alkyl, halo-lower alkyl, a...
|
|
WO/1999/001442A1 |
Compounds of formula (I), pharmaceutically acceptable salts or $i(in vivo) hydrolysable esters thereof, wherein: X is O, NH, CH¿2?; R?1¿ is an optionally substituted aryl ring, optionally substituted heteroaryl ring, or such ring syste...
|
|
WO/1999/000356A1 |
This invention relates to compounds of formula (I) which inhibit Factor Xa, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ame...
|
|
WO/1998/058646A1 |
The invention relates to the use of a somatostatin receptor ligand of nonpeptide origin, e.g. of general formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof, which has high and/or selective affinity to the somatostatin rec...
|
|
WO/1998/058934A1 |
The invention concerns novel 2-(iminomethyl)amino-phenyl derivatives, their preparation, their application as medicines and compositions containing them.
|
|
WO/1998/058677A1 |
The invention provides a pharmaceutical formulation comprising voriconazole, or a pharmaceutically acceptable derivative thereof, and a cyclodextrin derivative of formula (I), wherein R?1a-g¿, R?2a-g¿ and R?3a-g¿ independently represe...
|
|
WO/1998/058905A1 |
Amidrazone derivatives of formula (I) useful for prevention or treatment of lupus mycosis attributable to fungi, such as Candida, Aspergillus, and Cryptococcus, pharmaceutically acceptable salts thereof, and pharmaceutical compositions t...
|
|
WO/1998/057951A1 |
The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula (I) or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors ...
|
|
WO/1998/057954A1 |
This invention relates to piperazine derivatives of formula (I), wherein Y is bond or lower alkylene, R?1� is aryl which may have substituent(s), R?2� is aryl or indolyl, each of which may have substituent(s), R?3� is hydrogen or l...
|
|
WO/1998/057972A1 |
The present invention provides a compound of formula (I) wherein R is phenyl, C�3?-C�7? cycloalkyl or heteroaryl, each of which being optionally benzo- or C�3?-C�7? cycloalkyl-fused and optionally substituted, including in the be...
|
|
WO/1998/056788A1 |
Compounds of formula (I) are described in which R?1� is optionally substituted heteroaryl; R?2� is optionally substituted aryl or optionally substituted heteroaryl; R?3� is a group -L?1�-R?7� or -L?2�-R?8� [where L?1� is ...
|
|
WO/1998/055448A2 |
The invention relates to fluoroalkene carboxylic acid derivatives of general formula (I), in which R�1? and R�2? are hydrogen (independently of each other), or alkyl, a group of formula (II), cycloalkyl, alkenyl or alkynyl, which are...
|
|
WO/1998/055119A1 |
There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in bo...
|
|
WO/1998/054164A1 |
The present invention provides compounds which specifically inhibit FXa, which are effective when orally administered and which are useful as a safe medicine for the prevention or treatment of diseases caused by thrombus or infarction. C...
|
|
WO/1998/054172A1 |
This invention particularly relates to novel pyridylmethylsulfinyl benzimidazole represented by general formula (I), its tautomers, its derivatives, its analogs, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, i...
|
|
WO/1998/051665A2 |
This invention relates to macrocyclic molecules of formula (I) which inhibit metalloproteinases, including aggrecanase, and the production of tumor necrosis factor (TNF). The present invention also relates to pharmaceutical compositions ...
|
|
WO/1998/051311A2 |
This invention is directed to dihydropyrimidine compounds which are selective antagonists for human $g(a)�1A? receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholestero...
|
